Abgenix Could Choose From Abacom, Acrosan, Takrisar For MAb Therapy
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Abgenix may be considering the tradenames Abacom, Acrosan, Acrosar, Takrisan or Takrisar for its anti-CD147 monoclonal antibody therapy, ABX-CBL, in Phase II/III development for treatment of steroid-resistant graft-versus-host disease in bone marrow and stem cell transplants. The firm submitted the names to the Patent and Trademark Office for monoclonal antibody therapies to treat cancer and autoimmune, infectious, inflammatory and genetic diseases.